Intracapsular Injection of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis (KOA UC-MSCs)
Evaluating the Efficacy of Intra-articular Injection of Human Umbilical Cord Mesenchymal Stem Cells for Treating Knee Osteoarthritis
This is a self-controlled study comparing both knees. A total of 20 participants are planned to be enrolled. Among the first 10 participants, the same patient received 50 million mesenchymal stem cells and 2 ml of hyaluronic acid solution mixture in one knee as the experimental group, while the other knee was treated with 2 ml of hyaluronic acid injection solution as the control group. The first 10 patients did not experience any serious adverse events. After re-enrollment of the next 10 patients, the same patient was given 100 million mesenchymal stem cells and 2 ml of hyaluronic acid sodium mixture to one knee, while the other knee was given 2 ml of hyaluronic acid sodium injection as the experimental group. Compare the therapeutic effects between the two knees and among different doses.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Varhainen vaihe 1
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Patients with primary knee osteoarthritis aged between 45 and 75 years old;
- The X-ray of the bilateral knee joints shows a KL grade of 2-3 for both knees, and the grades of the bilateral knee joints are consistent;
- The difference in knee pain VAS score between both knees is no more than 2 points;
Exclusion Criteria:
- Those who have received joint cavity injection treatment within 3 months;
- Those who have experienced knee joint infection within 12 weeks, or knee joint injury within 12 weeks;
- Rheumatoid arthritis and other autoimmune joint diseases;
- Those with digestive tract ulcers, coronary heart disease and other conditions where the use of non-steroidal anti-inflammatory drugs is contraindicated;
- Those with tumors, diabetes, blood system diseases, local skin diseases and systemic allergies;
- Those with immunodeficiency or who have received immunosuppressive treatment within 12 weeks;
- Those with other serious diseases that cannot cooperate with the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: treatment group
First, 10 subjects were enrolled. For one knee joint of each subject, a mixture of 5 million HUCMSCs and 2 ml of sodium hyaluronate was administered as the experimental group. If no serious adverse reactions occurred among the first 10 patients, the remaining 10 subjects were enrolled, and the other knee joint of each subject was treated with 100 million HUCMSCs and 2 ml of sodium hyaluronate as the experimental group. |
Procedure for knee joint injection: The patient lies on their back, with the knee joint flexed at 90 degrees. The knee joint is disinfected with iodine and alcohol, and a sterile sheet is laid out. The puncture point for the knee joint is selected at the inner or outer knee crease or the supra-patellar bursa approach. Using a joint cavity puncture needle (a 19-gauge needle), insert the needle vertically through the skin at the puncture point. There is a slight sense of firmness when passing through the joint capsule, and a feeling of emptiness when it is broken through. There is no resistance when injecting the fluid, and the drug can be injected. |
|
Placebo Comparator: control group
The control group was given 2 ml of sodium hyaluronate.The control group was given 2 ml of sodium hyaluronate. |
Procedure for knee joint injection: The patient lies on their back, with the knee joint flexed at 90 degrees. The knee joint is disinfected with iodine and alcohol, and a sterile sheet is laid out. The puncture point for the knee joint is selected at the inner or outer knee crease or the supra-patellar bursa approach. Using a joint cavity puncture needle (a 19-gauge needle), insert the needle vertically through the skin at the puncture point. There is a slight sense of firmness when passing through the joint capsule, and a feeling of emptiness when it is broken through. There is no resistance when injecting the fluid, and the drug can be injected. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Adverse reaction grade
Aikaikkuna: From the beginning of the treatment to 28 days after the treatment.
|
Blood pressure was recorded during the transplantation process and on the 3rd, 7th, 14th and 28th days after the transplantation. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Aikaikkuna: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, record the heart rate. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Aikaikkuna: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, record the body temperature. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Aikaikkuna: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, observe whether any rash occurs. |
From the beginning of the treatment to 28 days after the treatment.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Clinical effectiveness
Aikaikkuna: From the beginning of the treatment to two years after the treatment
|
patient pain score (VAS score)： 0 point: Completely pain-free, no discomfort. 1-3 points (mild): There is pain, but it does not affect sleep or daily activities and can be tolerated; 4-6 points (moderate): Severe pain that significantly affects sleep, requiring distraction to cope with it, and usually requiring medication intervention; 7-10 points (severe): Significantly interferes with daily life, unbearable, may result in inability to move or sleep, requires strong pain relief. |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Aikaikkuna: From the beginning of the treatment to two years after the treatment
|
joint function score (KSS score) Including clinical scores and functional scores. |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Aikaikkuna: From the beginning of the treatment to two years after the treatment
|
quality of life score (SF-12) |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Aikaikkuna: From the beginning of the treatment to two years after the treatment
|
WORMS score |
From the beginning of the treatment to two years after the treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2026BJYYEC-XJS001
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-jakamista tukeva tietotyyppi
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .